VIM and ovarian cancer: Weingarten et al. (6) have determined that 1-4 h of T3 and T4 treatment drastically increases the expression of vimentin and reduces E-cadherin mRNA level to half of its basal level in OVCAR-3 and SKOV-3 ovarian cancer cell lines.